Financial Performance - The company's operating revenue for Q3 2025 was CNY 269,780,260.93, a decrease of 0.46% compared to the same period last year[5] - The net profit attributable to shareholders was CNY -9,655,087.06, representing a decline of 13.22% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -12,669,138.10, an increase of 19.09% compared to the previous year[5] - The net profit for the reporting period improved to -3,978,292.36, a 64.62% increase compared to -11,245,481.62 from the previous period[10] - The total comprehensive income increased to -2,433,341.98, reflecting a 78.51% improvement from -11,324,034.95[10] - The total profit for the current period is -6,964,537.49, an improvement from -8,696,470.58 in the previous period, reflecting a reduction in losses[23] - The basic earnings per share for the current period is -0.0315, compared to -0.0519 in the previous period, indicating a reduction in losses per share[24] Cash Flow and Assets - Cash flow from operating activities showed a significant increase of 195.54%, totaling CNY 37,761,959.61 year-to-date[5] - The company's cash and cash equivalents increased by 39.00%, reaching CNY 648,299,752.44, primarily due to the recovery of financial products and government subsidies[9] - The cash and cash equivalents at the end of the period rose to 623,435,189.73, a 49.47% increase from 417,084,606.49[11] - The company's cash flow from operating activities showed a significant improvement, with cash and cash equivalents at the end of the period increasing by ¥181,913,596.31[20] - The net cash flow from operating activities is 37,761,959.61, a turnaround from -39,525,496.61 in the previous period, showing a positive cash flow shift[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,527,949,433.55, reflecting a growth of 1.17% from the end of the previous year[5] - The total liabilities increased to ¥1,241,059,124.58 from ¥1,207,716,158.57, an increase of 2.7%[21] - The long-term borrowings increased by 52.49% to 277,177,390.88, up from 181,770,000.00[10] - The company recorded a 422.19% increase in current liabilities due to the reclassification of convertible bonds, totaling 247,271,977.40 compared to 47,353,275.53[10] - Non-current assets rose to ¥1,240,182,517.93 from ¥1,165,133,901.52, reflecting a growth of 6.4%[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,178, with no preferred shareholders[13] - The largest shareholder, Yan Jinyuan, holds 26.72% of the shares, totaling 70,705,185 shares[14] - Wang Shi, a significant shareholder, owns 2.46% of the shares, amounting to 6,497,280 shares, with 2,980,000 shares pledged[14] - The company has a total of 2,970,600 shares held in the repurchase special securities account, representing 1.12% of the total shares[14] - As of the end of the reporting period, the total number of restricted shares held by Yan Jinyuan is 53,028,889 shares, which are subject to management lock-up[15] Government Subsidies and Other Income - The company recorded a total of CNY 3,992,414.97 in government subsidies during the reporting period, contributing to its financial performance[7] - The company received government subsidies, which increased cash inflow from operating activities by 122.06%, totaling 83,936,745.51 compared to 37,799,137.53[11] - The company reported a significant increase in cash flow from operating activities, reaching 37,761,959.61, a 195.54% improvement from -39,525,496.61[11] - The company experienced a 206.75% increase in other comprehensive income, amounting to 1,544,950.38 compared to -78,553.33 in the previous period[11] - The investment income decreased significantly by 80.67%, amounting to 1,194,804.62 compared to 6,180,237.47 in the previous period[10] Management and Governance - The company has completed the board of directors' re-election and the appointment of senior management personnel[17] - The company plans to hold its second extraordinary general meeting of 2025 on August 1, 2025, to discuss board nominations[16] - The company has not reported any changes in the shareholding structure due to the transfer of shares for margin trading[15] - The company has not disclosed any new product developments or market expansion strategies in the current report[18] - The financial statements for the quarter ending September 30, 2025, are pending publication[18]

关于 2025 年前三季度利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 广东宝莱特医用科技股份有限公司（以下简称"公司"）于 2025 年 10 月 24 日召开第九届董事会第四次会议，审议通过了《关于 2025 年前三季度利润分 配预案的议案》，本议案尚需提交公司 2025 年第四次临时股东会审议。具体情 况如下： 一、关于利润分配预案的基本情况 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 证券代码：300246 证券简称：宝莱特 公告编号：2025-071 根据公司2025年第三季度财务报表（未经审计），公司2025年前三季度合并 报表实现归属于上市公司股东的净利润为-834.17万元，母公司报表归属于上市公 司股东的净利润为281.77万元。根据《中华人民共和国公司法》及《公司章程》 等相关规定，按母公司净利润提取10%的法定盈余公积金28.18万元后，截至2025 年9月30日，公司合并报表未分配利润为42,665.00万元，母公司报表未分配利润 为47,298.65万元，根据《深圳证券交易所上市公司自 ...

Core Points - Baolite announced that bondholders can choose to sell their "Baolite Convertible Bonds" at a price of 100.527 yuan per bond, including interest and tax [2] - Currently, the closing price of "Baolite Convertible Bonds" is higher than the repurchase price, which may lead to potential losses for investors who opt for the repurchase [2]

证券代码：300246 证券简称：宝莱特 公告编号：2025-067 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于回售期间"宝莱转债"暂停转股的提示性公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、债券代码：123065 2、债券简称：宝莱转债 根据《深圳证券交易所上市公司自律监管指引第15号——可转换公司债券》 的相关规定，发行可转债的上市公司可转债实施回售的，应当暂停可转债转股。 经向深圳证券交易所申请，"宝莱转债"在回售申报期间将暂停转股，即自2025 年10月29日（星期三）开始暂停转股，暂停转股期为五个交易日，至2025年11 月4日（星期二）止。自回售申报期结束的次一交易日（即2025年11月5日）起"宝 莱转债"恢复转股。上述暂停转股期间公司可转换公司债券正常交易，敬请公司 可转换公司债券持有人关注。 特此公告。 条件回售条款生效，具体内容详见公司同日于巨潮资讯网披露的《关于"宝莱转 债"回售的公告》（公告编号：2025-066）。 广东宝莱特医用科技股份有限公司 董事会 5、恢复转股时间：2 ...

证券代码：300246 证券简称：宝莱特 公告编号：2025-066 债券代码：123065 债券简称：宝莱转债 广东宝莱特医用科技股份有限公司 关于"宝莱转债"回售的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏。 特别提示： 7、回售期内暂停转股 8、"宝莱转债"持有人有权选择是否进行回售，本次回售不具有强制性 9、风险提示：持有人本次选择回售等同于以 100.527 元/张（含息税）的价 格卖出持有的"宝莱转债"。截至目前，"宝莱转债"的收盘价格高于本次回售价 格，投资者选择回售可能带来损失，敬请投资者注意风险。 广东宝莱特医用科技股份有限公司（以下简称"公司"）的股票自 2025 年 9 月 4 日至 2025 年 10 月 23 日连续三十个交易日的收盘价低于当期"宝莱转债"转 股价格（24.02 元/股）的 70%，且"宝莱转债"处于最后两个计息年度内，根据《广 东宝莱特医用科技股份有限公司创业板向不特定对象发行可转换公司债券募集 说明书》（以下简称"募集说明书"）的约定，"宝莱转债"的有条件回售条款生效， 现将"宝莱转债"回售有关事项公告如下： ...

广东精诚粤衡律师事务所 关于广东宝莱特医用科技股份有限公司 可转换公司债券回售的法律意见书 广东精诚粤衡律师事务所（以下简称"本所"）接受广东宝莱特医用科 技股份有限公司（以下简称"公司"或"宝莱特"）的委托，根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法 》（以下简称"《证券法》"）、《可转换公司债券管理办法》（以下简称 "《可转债管理办法》"）、《深圳证券交易所创业板股票上市规则》（以 下简称"《股票上市规则》"）、《深圳证券交易所上市公司自律监管指引 第 15 号——可转换公司债券》（以下简称"《自律监管指引第 15 号》"） 等现行有关法律、法规、规范性文件以及《广东宝莱特医用科技股份有限公 司创业板向不特定对象发行可转换公司债券募集说明书》（以下简称"《募集 说明书》"）的规定，本所律师对公司可转换公司债券回售（以下简称"本 次回售"）的相关事宜进行了审查，并出具本法律意见书。 本所律师根据本次回售所掌握的事实和公司提供的文件资料，按照现行 法律、法规的要求发表法律意见。为出具本法律意见书，本所律师对本次回 售所涉及的有关事项进行了审查，查阅了相关文件，并对有关问题 ...

在本次发行的可转换公司债券最后两个计息年度，如果公司股票在任何连续 三十个交易日的收盘价格低于当期转股价的 70%时，可转换公司债券持有人有权 将其持有的可转换公司债券全部或部分按面值加上当期应计利息的价格回售给 公司。若在上述交易日内发生过转股价格因发生送红股、转增股本、增发新股（不 包括因本次发行的可转换公司债券转股而增加的股本）、配股以及派发现金股利 等情况而调整的情形，则在调整前的交易日按调整前的转股价格和收盘价格计算， 在调整后的交易日按调整后的转股价格和收盘价格计算。如果出现转股价格向下 修正的情况，则上述"连续三十个交易日"须从转股价格调整之后的第一个交易 日起重新计算。 最后两个计息年度可转换公司债券持有人在每年回售条件首次满足后可按 上述约定条件行使回售权一次，若在首次满足回售条件而可转换公司债券持有人 未在公司届时公告的回售申报期内申报并实施回售的，该计息年度不能再行使回 售权，可转换公司债券持有人不能多次行使部分回售权。 财通证券股份有限公司 关于广东宝莱特医用科技股份有限公司 可转换公司债券回售有关事项的核查意见 财通证券股份有限公司（以下简称"财通证券"或"保荐机构"）作为广东 宝莱 ...

Group 1 - The company has a total of 397 patents as of the end of 2024, with 30 of these patents related to the nephrology medical sector [1] - The German subsidiary remains a wholly-owned subsidiary of the company, and any temporary information disclosure will be conducted in accordance with legal and regulatory requirements [1]

（编辑 袁冠琳） 证券日报网讯 宝莱特10月13日在互动平台回答投资者提问时表示，公司严格按照相关法律法规和监管 要求履行信息披露义务。根据信息披露规则，公司已在2024年年度报告中披露了各业务板块的营业收入 数据及主要子公司的经营数据。 ...

Core Viewpoint - Baolait's stock price has experienced a decline recently, with a year-to-date increase of 22.91% but a notable drop in the last 60 days of 13.46% [1] Group 1: Stock Performance - On October 13, Baolait's stock fell by 4.59%, trading at 8.10 yuan per share, with a total market capitalization of 2.143 billion yuan [1] - The stock has seen a net outflow of 2.0895 million yuan in principal funds, with large orders accounting for 20.69% of sales [1] - Over the past five trading days, the stock has decreased by 3.91%, and over the last 20 and 60 days, it has dropped by 8.37% and 13.46%, respectively [1] Group 2: Company Overview - Guangdong Baolait Medical Technology Co., Ltd. was established on June 28, 1993, and listed on July 19, 2011 [1] - The company specializes in the research, production, sales, and service of medical device products, with revenue composition: 77.51% from blood dialysis products, 21.39% from monitoring devices, and 1.10% from other products [1] - Baolait is classified under the pharmaceutical and biological industry, specifically in medical devices [1] Group 3: Financial Performance - As of June 30, Baolait reported a decrease in operating revenue to 523 million yuan, down 2.43% year-on-year, while net profit attributable to shareholders increased by 152.22% to 1.3134 million yuan [2] - The company has distributed a total of 244 million yuan in dividends since its A-share listing, with 35.1578 million yuan distributed in the last three years [3] Group 4: Shareholder Information - As of June 30, 2025, Baolait had 18,400 shareholders, a decrease of 6.12% from the previous period, with an average of 11,477 circulating shares per shareholder, an increase of 6.50% [2] - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund increased its holdings by 259,800 shares, while Hua Xia Zhong Zheng 500 Index Enhanced A became a new shareholder with 1,228,900 shares [3]